A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Autoimmune Hepatitis, immunoproteasome inhibition, selective proteasome inhibition, disease flare, Liver enzymes, ALT (alanine aminotransferase), AST (aspartate aminotransferase), glucocorticoids, steroids, Hepatitis A, Hepatitis, zetomipzomib, zetomipzomib in open-label extension
Lead Scientist at UCSF
- Michele Tana, MD
Michele Tana grew up in Northern Virginia, studied the Classics at Harvard College, and attended Harvard Medical School. She trained in internal medicine at Stanford University Hospital and Clinics and gastroenterology at California Pacific Medical Center.